Corporate Status ZeGen Medications is unlisted publicly and has no presence on stock exchanges
Still, there are many vitamins, minerals, and other dietary supplements that have been shown to improve thyroid function, reduce disease symptoms, and improve overall quality of life in people with thyroid disease
"Allowing compounding, while not the same as drug approval, is nonetheless a nod to regulatory recognition." This time, the FDA's advisors voted 7-5 in favor of putting MOTS-C on the compounding list
Whilst the market is currently led by Novo Nordisks semaglutide (Ozempic/Wegovy) and Eli Lillys tirzepatide (Mounjaro/Zepbound), stronger competition is expected as new entrants including Boehringer Ingelheim, Amgen, Pfizer and Roche offer novel mechanisms (dual agonists, triple agonists and amylins), formulations (oral vs injectable) and dosing regimens (daily vs weekly vs monthly)
Market Drivers: Why the GLP-1 Market is Expanding Now
Studies isolating cagrilintides postprandial glucose and glucagon effects from those of its combination partner